Reconstruction of critical size bone defects represents a major challenge in orthopaedic surgery. Insufficient angiogenesis is a limiting factor for engraftment of largescale tissue transplants. Transplantation or stimulation of local mesenchymal stem cells (MSCs) represents a potential solution to enhance angiogenesis. We recently identified angiogenic properties for the Toll-like receptor (TLR) 2/6 agonist MALP-2 and now investigated if MALP-2 could be used to stimulate MSCs in order to promote angiogenesis in vitro and in vivo.
Introduction
Regeneration of critical size bone defects remains a major problem in orthopaedic surgery. Bone is a highly vascularised tissue reliant on the close spatial and temporal connection between blood vessels and bone cells to maintain skeletal integrity. In this regard, insufficient angiogenesis is a limiting factor for larger scale tissue engineering of bone (Kanczler and Oreffo, 2008) . Novel methods -e.g., cell based therapies -seem to be promising approaches in regenerative medicine. In particular by using mesenchymal stem cells (MSCs), good results have been reported for bone tissue engineering in a number of clinical studies (Gómez-Barrena et al., 2011) .
Toll-like receptors (TLRs) are initially discovered as receptors of the innate immune system recognising pathogen-associated molecular patterns (PAMPs) from invading pathogens in order to organise the body's immune defence via the activation of inflammatory pathways (Takeda et al., 2003; Brown et al., 2011) . Later reports identified the ability of TLR family members to recognise likewise endogenous ligands, which accumulate during tissue damage and fibrosis with important functions in the regulation of non-infectious inflammation (Yu et al., 2010) . Of note, a new role for TLRs in wound healing (Deiters et al., 2004; Macedo et al., 2007) and liver regeneration (Seki et al., 2005) has been reported, suggesting even a regenerative aspect for TLR signalling.
Macrophage-activating lipopeptide of 2 kDa (MALP-2) is a bacterial lipopeptide which naturally occurred in mycoplasma species (Muehlradt et al., 1997) and is recognised by a heterodimer of TLR2 and TLR6 (Takeuchi et al., 2000; Takeuchi et al., 2001) . Of note, MALP-2 is synthetically available and has been already used in multiple studies. MALP-2 stimulation of the immune response has potential therapeutic implications, e.g., as a mucosal adjuvant for vaccination (Rharbaoui et al., 2002) or to induce lipopolysaccharide cross tolerance (Deiters et al., 2003) . In oncology, intratumoural application of MALP-2 leads to significant tumour suppression in mice with pancreatic cancer (Schneider et al., 2004) . In a phase I/II trial, injection of MALP-2 into incurable pancreatic tumours lead to prolonged survival of these patients. This was potentially explained by immune activation including attraction of natural killer cells, activation of macrophages and dendritic cells, and lymphocyte infiltration (Schmidt et al., 2007) . In addition, MALP-2 exhibits even tissue regenerative potential. Topical treatment of full-thickness excision skin wounds in diabetic mice with MALP-2 led K Grote et al. TLR2/6 
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to a significantly accelerated wound healing. This effect was accompanied by stimulation of the inflammatory response with activation of macrophages and increased capillary density in the wound bed. Genes encoding for growth factors such as vascular endothelial growth factor (VEGF), and granulocyte-macrophage colony-stimulation factor (GM-CSF) were found to be up-regulated by MALP-2 treatment (Deiters et al., 2004) . In this regard we showed that TLR2/6 stimulation by MALP-2 directly promote angiogenesis, a mechanism that is driven by GM-CSF induction in endothelial cells and monocytes (Grote et al., 2010) . Moreover, recent data from our group even demonstrated a therapeutic potential of MALP-2 to accelerate endothelial wound healing after interventional vascular injury (Grote et al., 2013) . Interestingly, there are in vitro studies showing that MALP-2 can even stimulate bone resorption by an IL-6-dependent mechanism (Piec et al., 1999) . MSCs are able to differentiate into cell types such as osteoblasts, chondrocytes, and adipocytes. The expression of TLRs in MSC has already been proven with important functions for differentiation, migration, proliferation and survival of these cells (Pevsner-Fischer et al., 2007; DelaRosa and Lombardo, 2010) . In addition, MSCs are a rich source of soluble pro-angiogenic growth factors such as VEGF in response to different stimuli (Crisostomo et al., 2008) . Modulation of local or transplanted MSCs may represent a promising tool for tissue engineering. The aim of the present study was to investigate potential pro-angiogenic effects of MALP-2 on MSCs for the use of therapeutic angiogenesis in tissue engineering. Therefore, we used human MSCs for in vitro studies and MSCs from sheep for subsequent in vivo studies.
Materials and Methods

Cell culture
Isolation and cultivation of human MSCs 20-80 mL of bone marrow aspirates from the iliac crest were collected from 3 donors undergoing transplantation of cancellous bone. Two patients were operated electively (osteotomy), one underwent dorsal stabilisation for vertebral fracture after trauma. The donors were otherwise healthy and their age ranged between 46 and 55 years. No patient was administered dexamethasone or other steroids before harvesting. At first, the bone marrow aspirates were diluted in a heparin-solution and stored at 4 °C in the syringe. Within 12 h after aspiration MSCs were isolated and cultivated as described before Broese et al., 2011) . Briefly, bone marrow aspirates were mixed 1:2 with Dulbecco´s Phosphate Buffered Saline (PBS, Biochrom, Berlin, Germany) and centrifuged over a Percoll gradient (Biocoll ® , Biochrom) for 20 min at 800 g. The white section of the supernatant was resuspended in PBS and centrifuged again for 20 min at 800 g. The obtained cell pellet was resuspended in Dulbecco's Modified Eagle's Medium (DMEM)/Ham´s F-12 culture media (Biochrom) supplemented with 10 % foetal calf serum (FCS, Gibco, Darmstadt, Germany), 100 U/mL penicillin, 100 µg/mL streptomycin (Gibco, Karlsruhe, Germany), 2.5 µg/mL amphotericin B (Biochrom), plated in 75 cm² culture flasks (Nunc, Berlin, Germany) and incubated at 37 °C and 5 % CO 2 in a humidified atmosphere. The medium was changed 3 times a week. After reaching confluence at day 14-21, the cells were released with 0.25 % trypsin (Gibco), counted and subcultured in 75 cm² cell culture flasks (Nunc). Cells between passage 2 and 4 were used for all experiments.
Cultivation of HUVECs
Human endothelial cells (human umbilical vein endothelial cells, HUVECs) were obtained from Lonza (Cologne, Germany). Cells were cultured in endothelial cell growth medium (EGM-2; Lonza) with growth factors (epidermal growth factor, vascular endothelial growth factor, fibroblast growth factor, insulin-like growth factor-I) supplemented with 2 % FCS, 100 U/mL Penicillin and 100 µg/mL Streptomycin in gelatin-coated 25 cm 2 cell culture flasks (Nunc). For starvation, HUVECs kept in endothelial basal medium (EBM-2, Lonza) without growth factors supplemented with 0.5 % FCS, 100 U/mL penicillin and 100 µg/mL streptomycin 24 h before experiments. EBM-2 medium without growth factors (control) and EGM-2 medium with growth factors (GF) were used as control conditions during experiments. Cells between passage 2 and 4 were used for all experiments.
CD34
+ cells The source of peripheral blood CD34 + cells was leukapheresis material from healthy donors after stem cell mobilisation with recombinant granulocyte-colony stimulating factor (G-CSF). For isolation of CD34 + cells, we used the CliniMACS system (Miltenyi Biotec, Bergisch Gladbach, Germany).
All procedures were approved by the institutional ethical committee of Hannover Medical School, Germany, and were in accordance with the Helsinki Declaration of 1975, as revised in 1983. An informed consent was obtained from all donors.
MALP-2
MALP-2 was purchased from Axxora GmbH (Loerrach, Germany) and dissolved in 30 % 2-propanol/water to a 1 mg/mL stock solution. MALP-2 was diluted in cell culture medium for further experiments.
Phalloidin staining F-actin filaments of MSCs of passage P2 and P4 were stained with Alexa Fluor ® 488 phalloidin (1:500, Invitrogen, Carlsbad, CA, USA) and nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI, 1:100,000, Invitrogen) by direct application to the cell culture medium for 2 hours. Pictures from the cells were taken with an inverted microscope (AxioObserver.Z1, Carl Zeiss, Jena, Germany) and a digital camera (AxioCam MRm, Carl Zeiss) at 100x magnification. 
Flow cytometry
Polymerase chain reaction (PCR)
Total RNA from human MSCs was isolated using TriFast-Reagent (peqLAB, Erlangen, Germany) and reverse-transcribed with SuperScript reverse transcriptase (Invitrogen), oligo(dT) primers, and deoxynucleoside triphosphates. Products were amplified using Taq DNA polymerase (Invitrogen). PCR was performed with an initial denaturation step at 95 °C for 10 min followed by 40 PCR cycles consisting of 95 °C for 15 s, 57 °C for 30 s, and 72 °C for 30 s with oligonucleotides for TLR2 (forward primer: 5´-TCA TTT GGC ATC ATT GGA AA-3´, reverse primer: 5´-CCA CTT GCC AGG AAT GAA GT-3´, 862 bp), TLR6 (forward primer: 5´-GAC CTA CCG CTG AAA ACC AA-3´, reverse primer: 5´-GAA TGT GCT TGG TGC ATG AG-3´, 921 bp) and GAPDH (forward primer: 5´-ACC ACC ATG GAG AAG GCT GG-3´, reverse primer: 5´-CTC AGT GTA GCC CAG GAT GC-3´, 527 bp). Oligonucleotides were obtained from MWG-Biotech (Ebersberg, Germany). For visualisation, PCR products were separated on a 1.0 % agarose gel and analysed using a gel image analysis system (GeneGenius, Syngene, Cambridge, UK).
Western blotting
Proteins from cellular extracts of human MSCs and THP-1 cells were separated by denaturing SDS-PAGE (10 %), and transferred to a PVDF membrane (GE Healthcare, Munich, Germany). Transferred proteins were probed with antibodies against TLR2 (1:500, eBioscience), TLR6 (1:500, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and GAPDH (1:5000, Santa Cruz BiotechnologyVisualization was accomplished using appropriate peroxidase-conjugated secondary antibodies, ECL solution, and ECL film (Hyperfilm ECL, GE Healthcare). Films were visualised using an image analysis system (GeneGenius, Syngene).
Protein array 1x10
6 human MSCs of passage P2 were cultured overnight in 1 mL DMEM/Ham´s F-12 medium per well of a 24-well plate (Nunc). Medium were changed and cells left untreated (control) or were stimulated with 1 µg/ mL MALP-2. Supernatants were collected 24 h after stimulation and analysed with a commercial protein array for human angiogenesis-related cytokines and growth factors (RayBiotech, Norcross, GA, USA) according to the manufacturer's instructions. In brief, membranes were blocked for 30 min with blocking buffer and incubated with 2 mL of supernatants (1:2 diluted with blocking buffer) overnight at 4 °C. After washing, biotin-conjugated antibody cocktail was added and again incubated overnight at 4 °C, followed by a 2 h incubation with streptavidinconjugated peroxidase at room temperature. Membranes were incubated with peroxidase substrate and exposed to ECL films (Hyperfilm ECL; GE Healthcare). Films were digitised and quantified densitometrically using an image analysis system (GeneGenius, Syngene) and the software Quantity One (Bio-Rad Laboratories, Hercules, CA, USA).
Enzyme-linked immunosorbent assay (ELISA) 1x10
4 human MSCs of passage P2 were cultured overnight in 100 µL DMEM/Ham´s F-12 medium per well of a 96-well plate (Nunc). Medium was changed and cells were left untreated (control) or were stimulated with 1 µg/mL MALP-2. In addition, MSCs were treated with antibodies against TLR2 (25 µg/mL, eBioscience) and TLR6 (25 µg/ mL, Santa Cruz) and appropriate control IgG (50 µg/mL), before stimulation with 1 µg/mL MALP-2. Supernatants were collected 24 h after stimulation and analysed for VEGF and GM-CSF protein levels by commercial ELISA (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's protocol with the help of a plate reader (µQuant, BioTek Instruments, Winooski, VT, USA).
Cell migration assay 1x10
5 HUVECs in 100 µL of EBM-2 were placed in the upper chamber of Transwell cell culture inserts (8 µm pore size; Corning Life Sciences, Amsterdam, The Netherlands). The lower chamber contained 600 µL EBM-2 (control) or EBM-2 supplemented with 10 % conditioned medium of human MSCs stimulated for 24 h with or without MALP-2 (1 µg/mL). EGM-2 with growth factors (GF) was used as positive control. 5x10 4 human MSCs in 100 µL DMEM/ Ham´s F-12 were placed in the upper chamber of Transwell cell culture inserts (8 µm pore size; Corning Life Sciences). The lower chamber contained 600 µL DMEM/Ham´s F-12 with or without MALP-2 (1 µg/mL). DMEM/Ham´s F-12 with 10 % FCS was used as positive control. Migration was carried out for 24 h at 37 °C and 5 % CO 2 . Migrated cells into the lower chamber were quantified by counting in a Neubauer chamber using an inverted cell culture microscope (CKX31, Olympus, Hamburg, Germany).
Cell proliferation assay 5x10
3 HUVECs per well were seeded in gelatine-coated 96-well tissue culture plates (Nunc) and maintained for 6 h in 100 µL EBM-2 per well. Subsequently, cells were cultured in 100 µL EBM-2 (control) or in EBM-2 supplemented with 10 % conditioned medium of human MSCs stimulated for 24 h with or without MALP-2 (1 µg/ mL). EGM-2 with growth factors (GF) was used as positive control. 5x10 3 human MSCs per well were seeded in 96-well tissue culture plates (Nunc) and maintained for 6 h in 100 µL DMEM/Ham´s F-12 per well. Subsequently, cells were cultured in 100 µL DMEM/Ham´s F-12 (control) or in DMEM with MALP-2 (1 µg/mL). DMEM/Ham´s F-12 with 10 % FCS was used as positive control. Cell proliferation was measured on the basis of DNA synthesis by 5-bromo-2'-deoxyuridine (BrdU) incorporation. The amount of BrdU incorporation for the last 4 h of the 24 h cultivation period was determined with a commercial colorimetric quantification kit (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's K Grote et al.
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protocol by measuring the absorbance at 450 nm with a plate reader (µQuant; Bio-Tek Instruments, Winooski, VT, USA).
Matrigel angiogenesis assay (endothelial tube formation)
7.5x10 3 HUVECs per well were seeded on 96-well tissue culture plates (Nunc) previously coated with 25 µL Matrigel (growth factor-reduced; BD Biosciences). Cells were cultured in 100 µL EBM-2 (control) or in EBM-2 supplemented with 10 % conditioned medium of human MSCs stimulated for 24 h with or without MALP-2 (1 µg/mL). EGM-2 with growth factors (GF) was used as positive control. After 24 h of culturing, tube-like structures were staining with the intracellular fluorescent dye 2',7'-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein acetoxymethyl ester (Sigma-Aldrich Chemie, Taufkirchen, Germany) diluted 1:5000 in phosphate-buffered saline for 15 min and subsequently visualised using an inverted fluorescence microscope (AxioObserver.Z1, Carl Zeiss Microimaging) and a digital camera (AxioCam MRm, Zeiss) at 50x magnification. Endothelial tube length per picture was determined by computer-assisted morphometric analysis (ImageJ, NIH, Bethesda, MD, USA) and presented as cumulative tube length in µm.
Matrigel angiogenesis assay (endothelial tube outgrowth)
The thoraco-abdominal aorta was isolated from C57BL/6 mice with the help of a surgical microscope (Stemi DV4 Spot, Zeiss). The aorta was cleaned of connective tissue and fat, and the adventitia were removed. Subsequently, the aorta was cut in segments of approximately 1 mm length and was placed on 48-well tissue plates (one segment per well, Nunc) previously coated with 50 µL Matrigel (growth factor-reduced; BD Biosciences). Segments were cultured in 1 mL EBM-2 (control) or EBM-2 supplemented with 10 % conditioned medium of human MSCs stimulated for 24 h with or without MALP-2 (1 µg/mL). EGM-2 with growth factors (GF) was used as positive control. After 7 days on Matrigel, the outgrowths of endothelial tubes were visualised using an inverted fluorescence microscope (AxioObserver.Z1, Zeiss) and a digital camera (AxioCam MRc, Zeiss) at 25x magnification. Tube length per aortic ring was determined by computer-assisted morphometric analysis (ImageJ) and presented as average tube length in µm. Endothelial origin of outgrowing tubes were confirmed by staining with fluorescein-labelled isolectin B4 (1:100, Vector Laboratories, Burlingame, CA, USA).
Sheep model of tissue engineering
Animal experiments were conducted at the University of Veterinary Medicine Hannover. The protocol was approved by the local ethics committee in accordance with the German federal animal welfare legislation (Department for Veterinary Affairs, Oldenburg, Germany, AZ:08/1621).
Eigtheen healthy adult female German Blackheaded sheep with an average body weight of 79.0 kg (range 64.5-85.0 kg) were used in the study. After intravenous (i.v.) induction (0.2 mg/kg midazolam, 5 mg/kg propofol), anaesthesia was maintained with isoflurane delivered in 100 % oxygen (1 L/min). Additionally, butarphanol (0.1 mg/kg intramuscularly (i.m.)), carprofen (4 mg/ kg subcutaneously (s.c.)), and buprenorphine (10 µg/ kg s.c.) were applied for analgesia. Monitoring during surgery included blood pressure, electrocardiogram, rectal temperature, and haemoglobin oxygen saturation. Surgery was performed in the right lateral position.
A muscle chamber of left latissimus dorsi muscle was prepared and gamma-sterilised β-tricalciumphosphate (TCP) cylinders (ChronOS ® , Synthes, Umkirch, Switzerland) were implanted. The porosity was 60-80 % and the pore size 100-500 nm. The cylinders had a length of 25 mm and a diameter of 14 mm and contained a standardised 7 mm hollow-drilled shaft. After hollow drilling, the cylinders were split longitudinally by a piezoelectric instrument. The artery/vein of the latissimus dorsi muscle was prepared microsurgically and positioned in the cylinder along the longitudinal split into the hollow drilling hole under sterile conditions. The β-TCP cylinders were differently loaded before the procedure. Three groups were created, each group consisted of 6 animals: group 1 (control group), group 2 (spongiosa group), group 3 (MALP-2 group).
For group 1 (control group): The β-TCP cylinders were saturated with 10 mL of autologous blood that was taken from the catheter in the jugular vein immediately prior to implantation. The blood was aspirated through the β-TCP cylinders by a special cartridge system (β-TCP kit, Synthes) until the cylinders were fully soaked. The scaffold was implanted into the left latissimus dorsi region via a 10 cm skin incision surrounding a perforator vessel bundle and the soft tissue wound was closed in layers using Vicryl 2.0 sutures.
For group 2 (spongiosa group): The β-TCP cylinder was blood-soaked using the β-TCP kit as described above. Then the scaffold was implanted into the left latissimus dorsi region via a 10 cm skin incision surrounding a perforator vessel bundle. After this, three bone punches (5 mm diameter) were harvested from the left iliac crest. The autologous cancellous bone was reduced into small pieces with an electric bone mill and then directly loaded on the cylinder in a surgical seeding procedure. Soft tissue wound was closed in layers using Vicryl 2.0 sutures.
For group 3 (MALP-2 group): Two surgical procedures were performed in this group. Three weeks prior to implantation, autologous bone marrow aspirates from the posterior left iliac crest were harvested. After a stab incision, the anterior and posterior outlines of the iliac crest were palpated by a Yamshidi aspiration needle. Then, the needle was inserted centrally and pushed into the marrow cavity approximately 5 cm deep following the contour of the cavity. MSCs were enriched as described above and cells were aspirated directly through a silicone tube into the porous scaffold using an aspiration technique described previously . The scaffolds of 2 β-TCP-cylinders were placed into a custommade bioreactor system. The bioreactor was filled with a medium (see below) and cultivated under continuous perfusion for 3 weeks. Of note, the bioreactor system has been described and used for clinical case studies of tissue-engineered bone before (Hesse et al., 2010) .
TLR2/6 stimulation of MSCs promotes angiogenesis Fig. 1 . Analysis of mesenchymal markers on human MSCs. Expression of CD73, CD271, CD45, CD235 (A) and CD34 (B) on human MSCs of passage (P) 2 and 4 was verified by flow cytometry using APC-and PE-labelled antibodies. Appropriate APC-and PE-labelled isotype IgG were used as controls.
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Briefly, it consists out of a culture chamber hosting a porous scaffold and an inflow and two outflow valves. For the cell seeding, one outflow valve is closed and one is open to permit aspirates to propagate through the scaffold pores. The bioreactors were filled with saline containing 1000 U of heparin (Liquemin ® ). The same solution was used to irrigate the aspiration syringe before its use. The bioreactor was rotated at 5° per minute for 24 h. Then, the scaffolds were perfused with 500 mL DMEM Ham´s F-12 medium (Biochrom) containing 10 % FCS, 100 U/ mL penicillin and 200 µg/mL streptomycin (Biochrom), 0.5 µg/mL amphotericin B (Biochrom), 5 µg/mL ascorbic acid (Sigma-Aldrich), 0.02 nM/mL dexamethasone (Merck, Darmstadt, Germany) (Jagodzinski et al., 2004) . In addition, the medium was supplemented with 30 ng/mL MALP-2. The bioreactor was kept in an incubator at 37 °C and culture was performed with a media flow of 2 mL/ min and 5 % CO 2 (Bancroft et al., 2002) . Every third day, 50 mL of culture media were exchanged. After 21 days, the bioreactors were disconnected and transferred to the operating room at 5 °C temperature.
Directly after removal from the bioreactor the loaded β-TCP cylinders were implanted onto the vessel bundle in the left latissimus dorsi muscle region as described above. Soft tissue wound was closed in layers using Vicryl 2.0 sutures. No extra harvesting of cancellous bone out of the iliac crest was performed. After 6 months, all bioartificial grafts were explanted and all animals were euthanised in deep sedation (midazolam 1 mg/kg i.m., propofol 5 mg/kg i.v., and pentobarbital 80 mg/kg i.v.). After explantation, the graft was fixed in 3.5 % neutral buffered formalin, embedded in methylmethacrylate (MMA) and sectioned perpendicular to the axis of the cylinder using a modified inner-hole diamond saw. Undecalcified slices of 30 mm thickness were surface stained with alizarine-methylene blue for standard light microscopy and histomorphometric analysis. Digital images of each slide were obtained using a Zeiss AxioImager MI Microscope fitted with an AxioCam MRc digital camera and AxioVision 4.5 software (Carl Zeiss, Oberkochen, Germany). The AxioVision module MosaiX was used to scan the total specimen. Digital images of the entire cross-section provided the basis for further analysis. Vascular structures (capillaries and arterioles) with a distinguishable lumen were counted in the area around the artery/vein and in the area of the scaffold.
Statistical analysis
Data are presented as the mean ± standard error of the mean (SEM). Comparisons were made by the 2-tailed Student's t-test for independent samples. Values of P less than 0.05 were considered statistically significant.
Results
Characterisation of human MSCs and analysis of TLR2 and TLR6 expression
MSCs were isolated from bone marrow aspirates from the iliac crest of patients undergoing cancellous bone transplantation and cultivated in vitro. Analysis by flow cytometry showed that the cells were highly positive (>80 %) for the mesenchymal markers CD73 and CD271 and negative for the leukocyte marker CD45 and the erythroid marker CD235 (Fig. 1A) . Expressions of the mesenchymal markers were found to be comparable in MSCs of passage 2 and 4. Of note, MSCs were negative for the haematopoietic marker CD34 excluding contamination with haematopoietic bone marrow cells (Fig. 1B) .
Since human MSCs between passage 2 and 4 were used for all subsequent experiments cells were initially characterised by phalloidin staining visualising F-actin filaments of the cytoskeleton. Cultured MSCs appeared homogenous with apparently no morphological difference between passage 2 and 4 ( Fig. 2A ). Next, we tested human MSCs for the expression of the MALP-2 receptors TLR2 and TLR6. Expression of TLR2 and TLR6 was detected on mRNA level by PCR (Fig. 2B) on protein level by Western blot (Fig. 2C ) and on the cell surface by flow cytometry (Fig. 2D ) and found to be comparable between passage 2 and passage 4.
MALP-2 promotes migration but not proliferation of human MSCs
We first assessed direct cellular effects of MALP-2 on human MSCs. Exposure to MALP-2 enhanced MSC motility since they significantly migrated alongside a MALP-2 gradient (Fig. 3A) . However, MALP-2 did not show any mitogenic effects on MSCs because cell proliferation was not enhanced upon MALP-2 treatment (Fig. 3B) .
Conditioned medium from MALP-2-stimulated human MSCs enhances migration, proliferation and tube formation of endothelial cells in vitro
Next, we investigated whether human MSCs exposed to MALP-2 may promote angiogenic properties of endothelial cells in a paracrine manner. Therefore, we used conditioned medium from MALP-2-stimulated human MSCs which was compared to conditioned medium from untreated human MSCs. Angiogenesis critically depends on migration and proliferation of endothelial cells; we addressed these issues in vitro using human endothelial cells (HUVECs). Compared to conditioned medium from untreated cells we observed significantly enhanced endothelial cell migration and proliferation with conditioned medium from MALP-2-stimulated human MSCs. Of note, already conditioned medium from untreated human MSCs increased migration and proliferation of HUVECs (Fig. 4A,B) . Angiogenesis describes the process of vessel sprouting from pre-existing vessels. Therefore, we investigated the generation of tubelike structures from HUVECs on Matrigel in vitro. We found that conditioned medium from MALP-2-stimulated human MSCs significantly increased the tube-like structure network on Matrigel as compared to conditioned medium from untreated human MSCs (Fig. 4C,D) . In addition, we performed another angiogenesis assay in vitro. Therefore, we isolated and subsequently cultivated murine aortic rings on Matrigel. In turn, conditioned medium from MALP-2 stimulated human MSCs significantly enhanced the outgrowth of endothelial tubes from aortic rings as compared to conditioned medium from untreated human MSCs (Fig. 4E,F) .
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MALP-2 induces the release of growth factors from human MSCs
To study the potential underlying mechanism for the observed angiogenic processes, we investigated factors that are released by human MSCs in response to MALP-2 and might be involved in angiogenesis. To this end, we stimulated human MSCs with MALP-2 and analysed the conditioned medium with the help of a commercially available protein array specific for angiogenesis-related cytokines and growth factors. Most factors on the array were already released by untreated human MSCs. However, several factors were released to a greater extend when human MSCs were stimulated with MALP-2 (Fig.  5A,B) . Among the strongest induced factors we identified GM-CSF (3.0-fold), monocyte chemotactic protein (MCP)-3 (6.2-fold), MCP-4 (2.9-fold) and platelet endothelial cell adhesion molecule (PECAM)-1 also known as CD31 (2.0-fold).
We performed further analysis of the conditioned medium by ELISA to confirm our protein array data for GM-CSF which we recently described as an autocrine factor of endothelial cells responsible for MALP-2-dependent angiogenesis. (Grote et al., 2010) . In addition; we investigated the major angiogenic factor VEGF, which 
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was not represented on the array. We detected a significant increase in GM-CSF and VEGF levels in the conditioned medium of MALP-2-stimulated human MSCs as compared to conditioned medium of not stimulated MSCs. MALP-2-dependent release of these factors could be blocked with antibodies against TLR2 and TLR6 demonstrating their important role in the process. Unspecific control IgG showed no effect (Fig. 5C,D) .
Implantation of MALP-2-treated autologous MSCs enhanced vessel density in the latissimus dorsi muscle of sheep
Finally, we performed a tissue engineering approach in sheep to assess angiogenesis in vivo. β-TCP cylinders loaded with autologous blood (control), autologous spongiosa or autologous MSCs co-cultivated with MALP-2 in a bioreactor system for 3 weeks were implanted into the left latissimus dorsi muscle of sheep. After 6 months vascular structures (capillaries and arterioles) were quantified in explanted grafts. Compared to the control group we found significantly more vessels in the MSCs + MALP-2 group in the region around the artery/vein (80.4 ±7.3 vs. 29.2 ±6.3, P < 0.01) as well as in the scaffold (67.6 ±9.0 vs. 38.8 ±4.7, P < 0.05) (Fig. 6A,B) .
Discussion
The major findings of the present study are as follows: (1) the MALP-2 receptors TLR2 and TLR6 are expressed in human MSCs; (2) MALP-2 directly induces migration of human MSCs; (3) MALP-2 stimulation of human MSCs enhances migration, proliferation and tube formation of endothelial cells in a paracrine manner; (4) MALP-2 induces the secretion of cytokines and growth factors from human MSCs; and (5) MALP-2 treated MSCs enhances vessel density in a sheep model of bone tissueengineering. Collectively, our study demonstrates that TLR2/6 stimulation of human MSCs by MALP-2 enhances angiogenic processes in a paracrine manner which could be used for therapeutic angiogenesis, e.g., in tissueengineering of bone. Transplantation of stem/progenitor cells are considered as potential therapy for inflammatory disorders, tissue repair, and gene delivery, among others (Rameshwar, 2012) . In this regard, a wide range of different type of stem cells such as embryonic stem cells, haematopoietic stem cells, MSCs and in the recent past induced pluripotent stem cells have been used (Armstrong et al., 2012) . The big advantage of the MSCs -used in the present studyis their relatively easy availability by isolation from bone marrow or from adipose tissue. MSCs have been already established for the treatment of various diseases including graft-versus-host disease, Crohn's disease, myocardial infarction, stroke, bone defects, diabetes, and wound repair, experimentally but also in various clinical studies (Vemuri et al., 2011; Wang et al., 2011) . Sufficient vascularisation of the engineered tissue is a crucial step in tissue-engineering in general and just as well accepted for tissue engineering of bone. Therefore, the simultaneous stimulation of osteogenic cell proliferation and angiogenesis remains one of the major challenges while developing substitute tissues for large scale bony defects (Kanczler and Oreffo, 2008; Gómez-Barrena et al., 2011) . MSCs are multipotent cells that participate in the structural and functional maintenance of connective tissues under normal homeostasis and are able to differentiate into several mesodermal cell lineages like adipocytes, chondrocytes, myocytes, osteocytes, and cells of haematopoietic supportive stroma (Pittenger et al., 1999) . However, MSCs have been shown to have multifaceted roles in the modulation of angiogenesis. On the one hand, MSCs act as mediators of angiogenesis during tissue repair following injury by the generation of bioactive molecules (Wu et al., 2007) . On the other hand, MSCs serve comparable roles in cancer by homing to developing tumours, where they exacerbate cancer cell proliferation and foster tumour angiogenesis (Cuiffo and Karnoub, 2012) .
Mammalian TLRs are homologues of the Drosophila Toll protein and were discovered in the mid-90s of the last TLR2/6 stimulation of MSCs promotes angiogenesis century (Taguchi et al., 1996; Medzhitov et al., 1997) . Initially, they were exclusively considered as sentinels of the immune system in order to organise the body´s pathogen defence in response to PAMPs of bacterial and viral origin by the activation of classical inflammatory signalling pathways such as the mitogen-activated protein kinase (MAPK) cascade or nuclear factor-κB (NF-κB) (Brown et al., 2011) . Over the years more and more TLR members -more than 10 in mice and human -have been discovered, which act as homo-or heterodimers. At the same time, the number of identified exogenous TLR ligands continuously increased and even endogenous TLR ligands, which mainly accumulate during tissue damage and fibrosis, have been described (Yu et al., 2010) . Furthermore, more recent work suggested a new role for TLRs in tissue regeneration and wound healing (Deiters et al., 2004; Seki et al., 2005; Macedo et al., 2007) . Likewise, the diacetylated lipopeptide MALP-2 -initially isolated from Mycoplasma species (Muehlradt et al., 1997) -was first described to activate immune cells, i.e. macrophages, via a heterodimer of TLR2 and TLR6 (Takeuchi et al., 2000; Takeuchi et al., 2001) . MALP-2 is so far one of the few definitely identified natural ligands signalling via this pathway. Of note, MALP-2 also exhibits a remarkable therapeutic potential and has been successfully used in different experimental and even clinical studies, ranging from dermal wound healing to anti-tumour treatment (Rharbaoui et al., 2002; Deiters et al., 2003; Schneider et al., 2004; Schmidt et al., 2007) . Of note, we uncovered a tissue regenerative capacity of MALP-2. In this regard, we reported that MALP-2 induced angiogenesis in a TLR2/6-dependent manner. The angiogenic process is particularly driven by the release of the growth factor GM-CSF from endothelial cells and monocytes and may represent an endogenous mechanism to restore capillaries in infected tissues in order to recruit immune cells for pathogen 
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defence (Grote et al., 2010) . Recently, we demonstrated that MALP-2 could be even used in a therapeutic manner to restore an endothelial damage after experimental vascular injury (Grote et al., 2013) . Thus, the beneficial effect of MALP-2 on vascular regeneration is already well documented in mice. In this regard, experiments in larger animals are required for a potential clinical use of MALP-2 in the future. In the present study, we went one step further and used human MSCs for in vitro studies and a complex sheep model for in vivo studies on therapeutic angiogenesis. TLR expression in MSCs was already reported, with implications to various cellular functions such as migration (Pevsner-Fischer et al., 2007; DelaRosa and Lombardo, 2010) . Accordingly, we were able to demonstrate TLR2 and TLR6 expression in cultured human MSCs of early passages, which were used for subsequent experiments. We observed that MALP-2 is a direct migratory but not mitogenic stimulus for human MSCs. In contrast to our data, Lei et al. (Lei et al., 2011) reported that TLR2 ligation suppressed MSC migration. However, Lei and colleagues used the triacetylated artificial Pam 3 Cys which signals differently from MALP-2, via a heterodimer of TLR2 with TLR1 (Lei et al., 2011) . Even though MSCs seem to be able to differentiate into endothelial cells under certain conditions (Oswald et al., 2004) , their reported angiogenic properties are widely regarded as paracrine effects (Kasper et al., 2007; Wang et al., 2011) . In line with this concept, we found that supernatants from cultured human MSC enhanced migration and proliferation of endothelial cells. We could not observe any effects on tube formation of endothelial cells with supernatants from human MSCs in our experiments. However, compared to these untreated supernatants, supernatants from MALP-2 pre-treated human MSCs significantly increased migration, proliferation and tube formation of endothelial cells, which are known as important cellular processes during angiogenesis. In this regard, MALP-2 has been shown to induce several cytokines and growth factors such as the major angiogenic factor VEGF from monocytes, which act as paracrine factors in angiogenesis and wound healing (Deiters et al., 2004) . We recently identified GM-CSF, which is secreted by endothelial cells in response to MALP-2 as the major autocrine factor for MALP-2-induced angiogenesis (Grote et al., 2010) . Similarly, we now found that MALP-2 induced the release of different factors with angiogenic properties from human MSCs including VEGF and GM-CSF. Taken together, we demonstrated that preconditioning of human MSCs with MALP-2 enhanced angiogenesis in vitro in a paracrine manner. This concept seems to be applicable to angiogenic therapy in vivo, since MALP-2 preconditioned MSCs enhanced vascular density in a sheep model of tissue engineering of bone. TLR activation in MSCs may represent a novel therapeutic approach, since Mastri et al. recently described that TLR3 activation augmented the release of trophic factors by MSCs and enhanced their therapeutic potency (Mastri et al., 2012) .
From our point of view, there are two different approaches to use the scientific gain of knowledge of our study for therapeutic angiogenesis in tissue engineering of bone: (1) a direct application of MALP-2, e.g., incorporated in or coated onto a scaffold matrix of an in vitro or in vivo engineered construct; or (2) an indirect application of MALP-2, e.g., in a cell transplantation approach with a defined MALP-2 treatment of the cells before or at the time of transplantation. We here started to investigate the latter approach by transplantation of MALP-2 treated human MSCs. In this regard, our in vivo study represents a pilot study to evaluate the potential of MALP-2-treated MSCs in an experimental model of tissue engineering. Further animal experiments are needed to compare different experimental settings and elucidate the optimal regime for a potential future clinical application of MALP-2 in therapeutic angiogenesis.
Conclusions
In summary, we here provide evidence that MALP-2 directly enhances the migration of human MSCs. In addition, MALP-2 promotes angiogenic processes such as migration, proliferation and tube formation of endothelial cells in a paracrine manner. Finally, we demonstrate that this concept is therapeutically applicable in an experimental sheep model of tissue engineering of bone. We detect significantly more capillaries and vessels after transplantation of constructs containing MALP-2 treated autologous MSCs. Related tissue-engineering concepts may be used for therapeutic angiogenesis in different regenerative applications.
